Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction
Preprint
Abstract
The human coronavirus HCoV-19 infection can cause acute respiratory distress syndrome (ARDS), hypercoagulability, hypertension, extrapulmonary multiorgan dysfunction. Effective antiviral and anti-coagulation agents with safe clinical profiles are urgently needed to improve the overall prognosis. We screened an FDA approved drug library and found that an anticoagulant agent dipyridamole (DIP) suppressed HCoV-19 replication at an EC50 of 100 nM in vitro . It also elicited potent type I interferon responses and ameliorated lung pathology in a viral pneumonia model. In analysis of twelve HCoV-19 infected patients with prophylactic anti-coagulation therapy, we found that DIP supplementation was associated with significantly increased platelet and lymphocyte counts and decreased D-dimer levels in comparison to control patients. Two weeks after initiation of DIP treatment, 3 of the 6 severe cases (60%) and all 4 of the mild cases (100%) were discharged from the hospital. One critically ill patient with extremely high levels of D-dimer and lymphopenia at the time of receiving DIP passed away. All other patients were in clinical remission. In summary, HCoV-19 infected patients could potentially benefit from DIP adjunctive therapy by reducing viral replication, suppressing hypercoagulability and enhancing immune recovery. Larger scale clinical trials of DIP are needed to validate these therapeutic effects.Keywords
All Related Versions
- Published version: Acta Pharmaceutica Sinica B, 10 (7), 1205.
This publication has 39 references indexed in Scilit:
- cAMP and Epac in the regulation of tissue fibrosisBritish Journal of Pharmacology, 2012
- Anti‐platelet therapy: phosphodiesterase inhibitorsBritish Journal of Clinical Pharmacology, 2011
- Immune Signaling by RIG-I-like ReceptorsImmunity, 2011
- SARS‐coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARSEuropean Journal of Clinical Investigation, 2009
- The discovery of angiotensin‐converting enzyme 2 and its role in acute lung injury in miceExperimental Physiology, 2008
- Platelet activation in acute pulmonary embolismJournal of Thrombosis and Haemostasis, 2007
- Loss of Angiotensin-Converting Enzyme-2 Leads to the Late Development of Angiotensin II-Dependent GlomerulosclerosisThe American Journal of Pathology, 2006
- Deletion of Angiotensin-Converting Enzyme 2 Accelerates Pressure Overload-Induced Cardiac Dysfunction by Increasing Local Angiotensin IIHypertension, 2006
- Dipyridamole Reversibly Inhibits Mengovirus RNA ReplicationJournal of Virology, 2005
- Inhibition of Herpes Simplex Virus Reactivation by DipyridamoleAntimicrobial Agents and Chemotherapy, 2001